By Hannah Green The Cambridge company behind the technology that enabled the first-ever pig-to-human kidney transplant earlier this year has raised a mega-round of funding. The biotech eGenesis said on Wednesday that it has closed a $191 million Series D financing led by Lux Capital. Existing investors including Arch Ventures and Leaps by Bayer, as well new investors, also […]
By Hannah Green Last year, Massachusetts’ life sciences industry saw its slowest job growth since 2017 as the industry faced economic headwinds. The Bay State’s biopharma workforce consisted of 116,937 employees in 2023, according to the latest “Industry Snapshot” report put out by the Massachusetts Biotechnology Council, or MassBio, on Tuesday. The trade group found that […]
The Biosecure Act could ban Chinese biotechs and hurt Mass. drug developers. But some see an opportunity for local R&D.By Hannah Green Driven by concerns over national security, the federal government is weighing a crackdown on Chinese biotechnology suppliers that would have far-reaching effects in the life sciences industry. The legislation, known as the Biosecure Act, would prevent biotech […]
By Jon Chesto When demand for office space cratered during the COVID-19 pandemic, many developersdoubled down on building lab space instead. Lately, it sure seems like they went overboard. With newly builtlife sciences buildings hitting the market at a much faster rate than they can be filled, the availability of lab space in Greater Boston […]
By Greg Ryan Five years ago, nearly half of the region’s lab space was in Cambridge, according to CBRE research. Today, about a third is. But a life sciences facility is not a “Field of Dreams.” Just because developers built labs in new places does not mean the biotechs will come — at least in this real estate market. […]
By Mark Heschmeyer Alexandria Real Estate Equities has extended the ground lease on its seven-building Technology Square campus in Cambridge, Massachusetts, from an affiliate of the Massachusetts Institute of Technology for 24 years at a cost of $270 million. The deal extends the term from January 2065 to December 2088, according to the San Diego-based firm’s […]
By Greg Ryan Boston-based The Davis Cos. has raised $977 million to invest in real estate such as apartments, labs and warehouses, closing the firm’s largest-ever fund amid a challenging time for fundraising in the sector. Institutional investors nationwide have turned away from real estate, instead putting their money into investments that offer close to the […]
By Hannah Green Massachusetts Biomedical Initiatives (MBI) is calling on state officials to designate Central Massachusetts as a “Biomanufacturing Hub” and help the region to compete against those in other states. The nonprofit released a regional biomanufacturing strategy on Tuesday. MBI wants to see the state get involved in such areas as building regional talent and incentivizing large-scale […]
By Hannah Green Venture capital funding to life sciences companies appears to be rebounding nationally after a few down years, according to new data from Pitchbook and the National Venture Capital Association. But that’s not the case among Massachusetts life sciences companies. Nationally, life sciences companies brought in $19.3 billion in the first six months of 2024. Last […]
By Hannah Green Eli Lilly and Co. is buying a Waltham biotech in a deal valued at around $3.2 billion. The startup being acquired is Morphic Holding Inc. (NASDAQ: MORF), a Waltham company working on treatments for chronic diseases such as types of inflammatory bowel disease. Indianapolis-based Lilly (NYSE: LLY) plans to acquire all outstanding shares of […]
